Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma - Final Assessment
Now that you have reviewed the self-study modules, answer the following questions to assess your gained knowledge of DLBCL.
Muhamad Alhaj Moustafa, MD, MS
Lymphoma Specialist at Mayo Clinic
Jacksonville, Florida
Muhamad Alhaj Moustafa, M.D., M.S., is a Hematologist and Medical Oncologist, with specialty interest in Lymphoma, Cellular Therapy, and Histiocytic diseases. His clinical and research focus includes: Hodgkin and Non-Hodgkin lymphoma, T-cell lymphomas, Post-transplant lymphoproliferative disorders, Rare subtypes of lymphoma, Histiocytic diseases, Radio-immunotherapy, Cellular therapy, Novel therapies for lymphoma.Dr. Alhaj Moustafa's primary emphasis in the clinic is to enhance patients' comprehension of their condition and encourage them to participate as active partners in their healthcare management. Apart from his clinical responsibilities, Dr. Alhaj Moustafa is actively involved in research and education, serving as a mentor to medical students, residents, and fellows. He produces authoritative materials and publishes them in high-impact scientific journals.
Allison C. Rosenthal, DO
Assistant Professor, Medicine Medical Director
Adolescent and Young Adult Cancer Program
Mayo Clinic, Phoenix, AZ
Allison C. Rosenthal, DO, is an assistant professor of medicine at the Mayo Clinic in Phoenix, AZ. She is also the medical director of the Mayo Clinic’s Adolescent and Young Adult Cancer Program and co-directs the CAR-T program. Dr Rosenthal received her medical degree from Arizona College of Osteopathic Medicine of Midwestern University in Glendale, AZ. She then completed her residency in internal medicine at the Creighton University School of Medicine and her fellowship in hematology and medical oncology at the Mayo Clinic College of Medicine and Science, both in Phoenix, AZ. Dr Rosenthal is board certified in internal medicine, hematology, and medical oncology.Dr Rosenthal treats patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Her clinical interests include the management and incorporation of novel treatment strategies for lymphomas, as well as the clinical care of the adolescent and young adult (AYA) population and their unique survivorship issues. Dr Rosenthal’s research interests include translational research (such as, bringing novel biomarkers into the clinic), participation in clinical trials looking at new drugs or combinations for patients with HL and NHL, and outcomes research (with a focus in the AYA population).
1.
Apply best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility, treatment selection, and sequencing of bispecifics in relation to CAR T therapies.
2.
Identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL.
3.
Integrate protocols to manage CRS and ICANS effectively when managing patients experiencing toxicities of bispecifics for treatment of R/R DLBCL.
4.
Create working relationships among community providers and those at comprehensive cancer centers in order to expand utilization of bispecifics to all patients who may benefit from therapy.
